SCL Healthcare participated in the American Society of Clinical Oncology (ASCO 2026), one of the world’s largest oncology conferences, to showcase its clinical trial analysis services and artificial intelligence (AI)-based cancer diagnostic technologies.

On 5 June, SCL Healthcare announced that it had taken part in the “2026 American Society of Clinical Oncology (ASCO),” held in Chicago, United States, from 29 May to 2 June.

ASCO is regarded as one of the world’s three major oncology conferences, along with the European Society for Medical Oncology (ESMO) and the American Association for Cancer Research (AACR). This year’s meeting was held under the theme “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide,” and was attended by approximately 40,000 experts from around the globe.

SCL Healthcare was selected for the fifth consecutive year to join as part of the Korean delegation organized by the Korea National Enterprise for Clinical Trials (KoNECT). The Central Lab (C-LAB) and the Companion Diagnostics Biomarker (CB) Center jointly participated in the event to introduce their core technologies and services.

C-LAB focused on pharmacokinetic (LC-MS/MS) analysis services used in the drug development process. In particular, in April it received additional designation for mass spectrometry items from the Ministry of Food and Drug Safety, expanding the scope of its specimen analysis services.

On this basis, it presented to pharmaceutical and biotech industry stakeholders its advanced analytical capabilities in areas such as in vivo kinetic analysis of antibody-drug conjugates (ADCs), peptide therapeutics, and anti-drug antibody (ADA) assessment.

The CB Center unveiled research成果 spanning from the discovery of biomarkers for disease diagnosis and prognosis prediction through to clinical application. These included a Korea-specific model for homologous recombination deficiency (HRD) gene testing to determine response to ovarian cancer therapies, and an AI-based early cancer detection technology using platelet genomic data.

In particular, the company explained that it is conducting research to extend the application of its currently developed multi-cancer early detection (MCED) technology into the field of minimal residual disease (MRD) analysis. An SCL representative stated, “Additional data related to MCED are currently being prepared,” adding, “Research outcomes in this area will be disclosed sequentially.”

Baek Se-yeon, COO of SCL Healthcare (and CEO of SCL Science), said, “Participating in ASCO for five consecutive years and being able to introduce our clinical trial analysis services and biomarker research capabilities to the global market has been highly meaningful,” and continued, “We will strengthen our competitiveness in digital healthcare, including AI diagnostics, and expand our role as a global partner in new drug development.”

Meanwhile, SCL Group, to which SCL Healthcare belongs, operates healthcare affiliates including Seoul Clinical Laboratories (SCL), Hanaro Medical Foundation, SCL Science, MediInfra, Qrologic, BioFoodLab, and Holmes AI.

Popular News